This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its third quarter 2013 financial results on Wednesday, November 6, 2013 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial (866) 318-8618 and use passcode 68040193. International callers may dial +1 (617) 399-5137, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at
If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 32541481 until midnight ET, November 20, 2013. International callers may access the replay by dialing +1 (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its marketing application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.